Frequencies of HER-2/neu Expression and Gene Amplification in Patients with Oesophageal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Mar 24

PMID 15785739

Citations 46

Authors

K Mimura

K Kono

M Hanawa

F Mitsui

H Sugai

N Miyagawa

A Ooi

H Fujii

Affiliations

Soon will be listed here.

Abstract

The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as immunotherapy for oesophageal cancer, is a novel and attractive approach. It is important to clarify the frequencies of HER-2 expression and gene amplification in patients with oesophageal squamous cell carcinoma (SCC) and to evaluate the relationship between HER-2 status and HLA haplotype, since the candidates for HER-2 peptide-based vaccination are restricted to a certain HLA haplotype. We determined the frequency of HER-2 expression using the HercepTest for immunohistochemistry and HER-2 gene amplification by fluorescence in situ hybridisation (FISH) assay in oesophageal SCC (n=66). HER-2-positive tumours (1+/2+/3+) analysed by a HercepTest were observed in 30.3% of all the patients and HER-2 gene amplification evaluated by FISH was observed in 11.0% of all the patients, in which all HercepTest (3+) tumours were found to have gene amplification and three of six moderately positive (2+) tumours showed gene amplification. Furthermore, HER-2-positive cells were present more diffusely and were larger within each tumour in the patients who were HercepTest 3+ than those who were HercepTest 1+. Moreover, the survival rate in HER-2-positive group was significantly worse than that in HER-2-negative group. Also, the survival rate in the patients with HER-2 gene amplification was significantly worse than that without HER-2 gene amplification. In addition, oesophageal SCC patients with both HLA-A24-positive and HER-2-positive tumours (1+/2+/3+) accounted for 26% of these cases, and both HLA-A2- and HER-2-positive tumours accounted for 18% of them.

Citing Articles

Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data.

Forbes A, Xu D, Cohen S, Pancholi P, Khurana E Cell Syst. 2024; 15(9):824-837.e6.

PMID: 39236711 PMC: 11415227. DOI: 10.1016/j.cels.2024.08.004.

Therapeutic vaccines for breast cancer: Has the time finally come?.

Corti C, Giachetti P, Eggermont A, Delaloge S, Curigliano G Eur J Cancer. 2021; 160:150-174.

PMID: 34823982 PMC: 8608270. DOI: 10.1016/j.ejca.2021.10.027.

Downregulation of miR-375 contributes to ERBB2-mediated VEGFA overexpression in esophageal cancer.

Ren S, Tan X, Fu M, Ren S, Wu X, Chen T J Cancer. 2021; 12(23):7138-7146.

PMID: 34729115 PMC: 8558641. DOI: 10.7150/jca.63836.

Antibody-Drug Conjugates for the Treatment of Breast Cancer.

Corti C, Giugliano F, Nicolo E, Ascione L, Curigliano G Cancers (Basel). 2021; 13(12).

PMID: 34207890 PMC: 8229763. DOI: 10.3390/cancers13122898.

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.

Chung W, Huang W, Liao W, Huang W, Liu Y, Su W Cancer Med. 2021; 10(7):2370-2379.

PMID: 33665980 PMC: 7982635. DOI: 10.1002/cam4.3824.

References

Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y . Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002; 62(20):5813-7. View

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y . Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994; 220(3):364-72; discussion 372-3. PMC: 1234394. DOI: 10.1097/00000658-199409000-00012. View

Kono K, Rongcun Y, Charo J, ICHIHARA F, Celis E, Sette A . Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer. 1998; 78(2):202-8. DOI: 10.1002/(sici)1097-0215(19981005)78:2<202::aid-ijc14>3.0.co;2-c. View

Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y . c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003; 57(5):1323-7. DOI: 10.1016/s0360-3016(03)00782-x. View

Kono K, Takahashi A, Amemiya H, Ichihara F, Sugai H, Iizuka H . Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int J Cancer. 2002; 98(2):216-20. DOI: 10.1002/ijc.10179. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Kato H, Watanabe H, Tachimori Y, Iizuka T . Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg. 1991; 51(6):931-5. DOI: 10.1016/0003-4975(91)91008-j. View

Disis M, Grabstein K, Sleath P, Cheever M . Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999; 5(6):1289-97. View

Perez E, Roche P, Jenkins R, Reynolds C, Halling K, Ingle J . HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77(2):148-54. DOI: 10.4065/77.2.148. View

10.

Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet J . Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer. 2000; 89(5):946-54. View

11.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

12.

Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M . Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res. 1993; 13(5A):1293-301. View

13.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

14.

Lam K, Tin L, Ma L . C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol. 1998; 24(5):431-5. DOI: 10.1016/s0748-7983(98)92403-9. View

15.

Maillet P, Baulieux J, Boulez J, BENHAIM R . Carcinoma of the thoracic esophagus. Results of one-stage surgery (271 cases). Am J Surg. 1982; 143(5):629-34. DOI: 10.1016/0002-9610(82)90181-7. View

16.

Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, Nukui H . Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res. 2004; 10(7):2538-44. DOI: 10.1158/1078-0432.ccr-03-0424. View

17.

Sliwkowski M, Lofgren J, Lewis G, Hotaling T, Fendly B, Fox J . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26(4 Suppl 12):60-70. View

18.

Altorki N, SKINNER D . En bloc esophagectomy: the first 100 patients. Hepatogastroenterology. 1990; 37(4):360-3. View

19.

Popescu N, King C, Kraus M . Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989; 4(3):362-6. DOI: 10.1016/0888-7543(89)90343-1. View

20.

Kono K, Takahashi A, Sugai H, Fujii H, Choudhury A, Kiessling R . Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002; 8(11):3394-400. View